Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
News|Articles|May 21, 2026

Why High-Concentration Biologics Demand a New Approach to Formulation Science

The biopharmaceutical landscape is undergoing a structural shift toward greater molecular complexity and formulation concentrations exceeding 100 mg/mL. High-concentration formulations, particularly those intended for subcutaneous administration, present a distinct set of technical challenges that conventional development approaches were not designed to address. Samsung Biologics’ proprietary S-HiCon™ platform provides an integrated, data-driven framework for navigating these challenges, encompassing early material generation, structured excipient screening, and advanced analytical characterization.


Related to this article

The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron and Alnylam’s cemdisiran (Livsayis) as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.
The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.